(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Eleven arrested over mass shooting in South Africa tavern - 2Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 310 Famous Frozen yogurt Flavors All over The Planet
- 4Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
- 5Why do people have baby teeth and adult teeth?
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
- Extraordinary Shows to Long distance race on a Plane
- Tens of thousands protest as far-right AfD forms new youth group
- ADHD drugs work, but not the way experts thought
- 6 Eyewear Brands Worth Purchasing
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
